Daejeon, South Korea

Jeiwook Chae

USPTO Granted Patents = 21 

 

 

Average Co-Inventor Count = 10.5

ph-index = 8

Forward Citations = 116(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents

Title: Jeiwook Chae: Innovations in Antibody-Drug Conjugates

Introduction

Jeiwook Chae is an accomplished inventor based in Daejeon, South Korea. With a remarkable portfolio of 19 patents, he has made substantial contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs). His innovative approaches have paved the way for advanced therapeutic methods.

Latest Patents

Chae's latest inventions focus on enhancing the efficacy of antibody-drug conjugates. One notable patent details ADCs that utilize branched linkers, allowing multiple active agents to be conjugated to an antibody. This inventive method involves the use of a branching unit that connects active agents through secondary linkers, promoting a more effective targeting mechanism with the potential for improved therapeutic outcomes. Another patent focuses on anti-CD19 antibody-drug conjugates, which have significant implications for treating CD19-positive malignancies. These conjugates utilize specific linkers to attach active agents to anti-CD19 antibodies, further broadening the scope of his groundbreaking work.

Career Highlights

Throughout his career, Chae has been associated with prominent biotechnology firms such as Legochem Biosciences, Inc. and Bioneer Corporation. His work in these companies has contributed to advancements in antibody engineering and drug delivery systems, establishing him as a key figure in the pharmaceutical innovation landscape.

Collaborations

In pursuing his innovations, Jeiwook Chae has collaborated with other notable professionals in the field, including Yong Zu Kim and Ho Young Song. These partnerships have helped amplify the impact of his research, fostering an environment of shared ideas and expertise that is crucial for groundbreaking advancements in biotechnological products.

Conclusion

Jeiwook Chae exemplifies the spirit of innovation in the biopharmaceutical industry. His extensive patent portfolio and collaborative efforts underscore his commitment to developing effective therapeutic solutions. As he continues to push the boundaries of scientific research, his work remains vital in the fight against challenging diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…